Discover the Idiopathic Pulmonary Fibrosis (IPF) Pipeline Exhibits Strong Pipeline With 95+ Drug Candidates

The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.


Browse the Report Summary at:

As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor. The analysis was also done based on route of administration and it was found that major drug candidates are being developed to be administered by oral route.


Download Free Sample of This Research Report:


U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.


Make Enquiry Before Buying the Report:

The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.

IPF Pipeline Analysis

  • By target
  • By route of administration
  • By company
  • By phase



Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +18887787886 (USA/Canada)



Connect with us: LinkedIn | Twitter | Google + | Facebook

%d bloggers like this: